Jove
Visualize
Contact Us

Related Experiment Videos

[Statins for cardiovascular prevention. Lowering LDL cholesterol, the primary objective].

Jean-Charles Fruchart1

  • 1Département de recherche sur les lipoprotéines et l'athérosclérose, UR 545 Inserm et Université de Lille 2, Institut Pasteur 1, rue du Professeur Calmette 59019 Lille. Jean-Charles.Fruchart@pasteur-lille.fr

Presse Medicale (Paris, France : 1983)
|October 16, 2002
PubMed
Summary

Lowering LDL-cholesterol is crucial for cardiovascular health, especially in high-risk patients. New strategies aim for even lower levels to improve prevention and reduce cardiovascular events.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lessons from PROMINENT and prospects for pemafibrate.

Cardiovascular diabetology·2024
Same author

Effect of Pemafibrate on Diabetic Foot Ulceration and Gangrene: An Exploratory Analysis From PROMINENT.

Journal of the American College of Cardiology·2024
Same author

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.

The New England journal of medicine·2022
Same author

Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non-Alcoholic Steatohepatitis.

Cells·2022
Same author

Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?

Current atherosclerosis reports·2021
Same author

Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?

Current atherosclerosis reports·2020
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Cardiology
  • Lipid Metabolism

Context:

  • Low-density lipoprotein cholesterol (LDL-C) is a primary cardiovascular risk factor.
  • A continuous relationship exists between LDL-C levels and cardiovascular events.
  • Statin interventions demonstrate significant reductions in cardiovascular risk and mortality.

Purpose:

  • To emphasize the importance of aggressive LDL-C reduction for cardiovascular prevention.
  • To highlight the challenges in achieving therapeutic goals in clinical practice.
  • To explore novel therapeutic strategies for further LDL-C lowering.

Summary:

  • Aggressive LDL-C reduction (< 1 g/l) is recommended for secondary prevention and high-vascular-risk patients.
  • Current therapeutic targets are frequently unmet, necessitating advanced treatment approaches.

Related Experiment Videos

  • Potential strategies include combination therapy with cholesterol absorption inhibitors or more potent statins.

    • Impact:

    • Achieving lower LDL-C levels can further reduce cardiovascular risk.
    • Comprehensive management of all cardiovascular risk factors is essential.
    • Optimizing lipid management is key to enhancing cardiovascular outcomes.